chest discomfort and haemoptysis, as well as constitutional symptoms such as weight loss and fatigue. 3 Long-term oral triazole antifungal therapy is the cornerstone of management for patients with CPA. 2 Itraconazole is generally considered the most appropriate first-line choice of treatment due to its efficacy in controlling symptoms and progression of CPA, a relatively favourable safety profile and low cost. 2, 4 Voriconazole or posaconazole can be used as alternative treatments in cases of clinical or microbiological antifungal resistance, or treatment intolerance. At our Centre, voriconazole is used as the second-line agent after itraconazole. In patients with pan-azole resistance, treatment intolerance or where oral triazole therapy is unsuitable, either an intravenous echinocandin or amphotericin B may be effective. 3, 5 In patients with limited disease, surgical intervention may be an option. 3 Isavuconazole is a new triazole antifungal agent licensed for the treatment of invasive pulmonary aspergillosis and mucormycosis. 6 Development of isavuconazole as a new antifungal was an important breakthrough in the treatment of Aspergillus infections due to the steady rise in azole resistance and unfavourable side effects seen with use of previous azoles. 7 The oral formulation has a high bioavailability of 98% and does not require food to be taken at the time of dosage, unlike certain itraconazole and posaconazole formulations. 7 Isavuconazole shows extensive tissue distribution and protein binding. 8 Isavuconazole has also been shown to have a higher or equivalent fungicidal activity against A fumigatus compared with posaconazole and voriconazole, and can often show activity against isolates resistant to itraconazole, caspofungin and amphotericin B.
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Isavuconazole has a favourable toxicity profile and fewer drug-drug interactions compared to the other triazoles. There is no requirement for isavuconazole dosage adjustment based on age or renal function impairment. 6, 9 Careful and regular monitoring of serum drug concentrations is recommended during triazole antifungal therapy to assure therapeutic levels and to avoid toxicity, complications associated with drugdrug or drug-food interactions and the development of antifungal resistance. 10, 11 Triazole cross-intolerance is common for patients who are on long-term therapy for CPA. 12 Therapeutic drug monitoring (TDM) is usually required for itraconazole, voriconazole and posaconazole. 11 However, there is insufficient evidence from "realworld" data to recommend routine TDM of isavuconazole in patients on long-term therapy. The aim of this study was to evaluate how patients with CPA tolerate isavuconazole compared with voriconazole and what the role of TDM is in this.
| PATIENTS AND ME THODS

| Study setting and design
We performed a retrospective observational study to investigate adverse events related to isavuconazole and voriconazole in patients with CPA receiving treatment at the National Aspergillosis Centre (NAC) based at Wythenshawe Hospital, Manchester University NHS Foundation Trust (MFT), Manchester, UK. Consecutive patients with CPA who had been prescribed either isavuconazole or voriconazole were identified and observed for a period of 12 and 6 months, respectively, prior to December 2016. in serum alanine aminotransferase (ALT) more than three times the upper limit of normal (55 IU/L) was used as a marker of hepatotoxicity. Clinical failure was defined as radiological, serological, mycological or symptomatic worsening of disease despite antifungal therapy. 4 The antifungal dose was adjusted with respect to the serum pre dose drug levels as per local protocols.
| Patients
| Statistical analyses
Data were analysed using graphpad prism version 7.0d (GraphPad Software, La Jolla, CA, USA). Categorical data are presented as frequencies and percentages, and continuous data as means and standard deviations or as medians and ranges. Chi-square or Fisher's exact tests were used to compare categorical variables. For normally distributed continuous variables, we used independent sample t tests, and for non-normally distributed variables, we used Mann-Whitney U tests to compare tolerability of voriconazole with that of isavuconazole. Statistical significance was at the 5% level for all analyses.
| RE SULTS
| Patient demographics
During the study period, 20 patients were commenced on isavuconazole and 21 patients were initiated on voriconazole. Patients commenced on isavuconazole had a median age of 65 (range: 53-84)
years, and 14 (70%) of these were males. Patients starting voriconazole had a median age of 66 (range: 37-78) years, and 12 (57%) of these were males. There were no significant differences in the demographic characteristics or the underlying conditions between the two groups (Table 1) .
| Adverse events
| Isavuconazole
All 20 patients receiving isavuconazole were commenced on a standard regimen (200 mg once daily by mouth). Twelve patients (60%) administered isavuconazole developed an adverse event during the 12-month follow-up period. Of these 12 patients, eight patients (35%) discontinued isavuconazole while four (20%) patients had their dose adjusted. A total of 11 patients (55%) had their therapy discontinued, of these, eight patients (40%) experienced adverse events and one patient (5%) had a pan-azoleresistant isolate of A fumigatus ( Table 2 ). The median duration of therapy before discontinuation was 6.0 (range: 2-11) months. The final two patients (10%) met the criteria for clinical failure, defined as radiological, serological, mycological or symptomatic worsening of disease despite antifungal therapy (Table 2) . Five (25%) patients in the isavuconazole group who were intolerant to other triazoles tolerated the standard dose of isavuconazole (Table 2) .
For the nine patients who continued therapy, four patients (44%)
had their maintenance dose reduced (halved, 100 mg OD) due to adverse events, three patients (33%) remained on the standard 200 mg once daily maintenance dose and two patients (22%) were on alternate day dosing (100 mg/200 mg; Figure 1A ). In relation to serum isavuconazole levels, only one patient (Isavu2, Table 2) experienced serious liver toxicity that was assumed to be due to the patient's high serum drug level.
| Voriconazole
Of the 21 patients commenced on voriconazole, 18 patients (86%) developed adverse events. None of the patients receiving voriconazole experienced clinical failure. Ten (48%) patients discontinued voriconazole therapy, all of whom had adverse events ( Figure 1B ).
Eight patients who reported adverse events continued voriconazole at a reduced dose. Six of the patients who discontinued voriconazole had previously received an azole, while four were treatment naïve ( Table 2 ). The median duration of therapy before discontinuation was 2.5 (range: 2-3) months. Three patients had more than one adverse event leading to discontinuation of voriconazole, and none of the patients had liver toxicity (Table 2) . Eleven patients (52%) who received voriconazole had previously been on itraconazole for CPA, and 10 were treatment naive. The median dose of voriconazole prescribed at the time of commencement of therapy was 400 mg (range:
300-500 mg) per day. Eleven (52%) patients remained on voriconazole for the whole 6-month period, 5 (45%) of whom remained on the same dose as originally, and doses were reduced in 3 (27%) and increased in 3 (27%) patients. 
| Isavuconazole compared to voriconazole
| D ISCUSS I ON
In this retrospective observational study on the tolerability of isavuconazole and voriconazole in CPA patients, more patients tolerated isavuconazole compared to voriconazole. However, the proportions of patients who discontinued both agents were similar. In contrast, in the SECURE trial, 6 permanent drug discontinuation due to drugrelated adverse events was less common with isavuconazole than with voriconazole (21 [8%] vs 35 [14%]). However, adverse event rate of 60% in the isavuconazole group is high and the reasons for this observation could be a subject for future studies. A greater proportion of patients receiving voriconazole experienced skin-and/or eyerelated side effects compared to patients receiving isavuconazole (52% vs 10%). Skin and eye adverse effects are well characterised in voriconazole use. 13 The most common side effects seen with isavuconazole use were neurologically related (25%), liver toxicity (15%) and skin-related (15%).
One patient on isavuconazole had high serum levels (>7.5 mg/L) which lead to discontinuation of therapy due to liver toxicity. Three patients (15%) receiving isavuconazole experienced liver toxicity, compared to none of the voriconazole patients. Previous studies suggest that isavuconazole would not require serum drug level monitoring. 13 However, the results of this study show that some groups of patients may benefit from TDM, especially those with adverse drug reactions and those with poor response to treatment.
Adverse events experienced by patients following prior triazole therapy did not predict the adverse reaction that developed while on voriconazole. None of the voriconazole patients who had previously received itraconazole presented the same adverse events with voriconazole as they had with itraconazole. However, six (30%) of the 20 patients who received isavuconazole presented with similar adverse events to those experienced on previous azoles, across all classes of adverse events except liver, and 25% of patients who were intolerant to other azoles tolerated the standard dose of isavuconazole.
The SECURE study found the most common adverse events to both drugs to be gastrointestinal-related (68% of isavuconazole patients vs 69% of voriconazole patients). This is in contrast with the findings of the present study where gastrointestinal adverse events were only seen in 5% of isavuconazole patients and 19% of voriconazole patients. Interestingly, the SECURE study found a much greater number of voriconazole patients with liver toxicity (16%) compared to isavuconazole patients (9%), contradictory to the 15% of isavuconazole patients and no voriconazole patients in this study with liver toxicity. 6 This difference could be due to the SECURE trial only using the standard dose of voriconazole without monitoring of serum drug levels, whereas in this study, dose changes were made in response to aberrant serum drug levels. In conclusion, we saw a similar proportion of patients discontinuing isavuconazole or voriconazole treatment due to adverse events.
Less than a third of the patients experienced similar adverse events with isavuconazole as with the prior azoles, with neurologically related adverse effects being the most common. A quarter of patients who were intolerant to other azoles tolerated the standard dose of isavuconazole and a third were able to continue therapy on a reduced dose. Isavuconazole adds to the treatment armamentarium for the long-term management of patients with CPA and may be an option for those patients who are intolerant to other triazoles, but further study of isavuconazole adverse effects in CPA patients would be welcomed.
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